Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics launches ß-Hydroxybutyrate Strip Test at AACC 2013

Published: Wednesday, July 24, 2013
Last Updated: Wednesday, July 24, 2013
Bookmark and Share
STAT-Site M ß-HB sets standard of care in ketone testing for DKA assessment.

EKF Diagnostics announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking. The new quantitative strip-based test for ß-Hydroxybutyrate (ß-HB) provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds. STAT-Site M ß-HB will be premiered at Booth #3614 at the American Association for Clinical Chemistry’s Annual Meeting and Clinical Lab Expo (AACC 2013) in Houston, 30th July to 1st August.

The presence and degree of ketosis can be rapidly assessed at the point-of-care by accurately measuring blood levels of ß-HB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides useful information to provide quality care when monitoring DKA in newly diagnosed patients, whilst also reducing time and costs in an intensive care unit setting.

Also at AACC, highlighting the clinical utility of ß-HB for the screening and diagnosis of ketosis, the AACC Industry Workshop ‘Metabolic Disturbances That Lead to ß-Hydroxybutyrate and Ketone Bodies’ will be hosted by EKF on Tuesday July 30, 7–8 am.  This will be presented by point-of-care specialist Dr. James Nichols, Professor of Pathology, Microbiology & Immunology and Medical Director of Clinical Chemistry at Vanderbilt University School of Medicine. Attendees will learn about the critical inter-relationships of glucose, diabetes mellitus and conditions that lead to DKA. Early reservation via marketing@stanbio.com is recommended as seating is limited.

Booth #3614 will play host to other very recently launched EKF products. These include another strip-based test for the rapid point-of-care analysis of hemoglobin for anemia determination, STAT-Site M Hgb. This hand-held analyzer combines low cost per test with portability and reliably delivers accurate hemoglobin results within 30 seconds from 15 µL of finger-prick whole blood.

AACC delegates will also have the opportunity to meet the new EKF Molecular Diagnostics’ team and view research use only products for cancer gene mutation enrichment and companion diagnostic applications.  These include newly introduced PointMan™ DNA Enrichment kits which comprise three kits for enriching mutations in BRAF, KRAS and EGFR T790M genes associated with melanoma (skin cancer), colorectal and lung cancers. PointMan kits offer highly-specific and ultra-sensitive enrichment of mutant genes in a background of wild-type (normal) genes that is unmatched by existing technologies.

Julian Baines, Group CEO, commented, “This year’s AACC Clinical Lab Expo is the first time we have showcased our new EKF Molecular Diagnostics cancer gene detection technology portfolio alongside our clinical chemistry and near-patient testing products. Our experts will be on hand to discuss our ever broadening range of innovative and high-quality IVD diagnostics products. These are designed to rapidly and accurately detect and manage diabetes, anemia, lactate and kidney related diseases, as well as support better informed decisions on patient treatments through companion diagnostics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!